Date: 2013-03-08
Type of information:
Compound:
Company: Galapagos (Belgium) Roche (Switzerland)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease: fibrosis
Details: Galapagos has announced that it agreed with Roche to end their alliance in fibrosis. Roche will make a payment of €5.75 million to Galapagos for work completed in 2012, contributing to 2012 Group revenues. With the ending of the alliance, Galapagos has regained the worldwide rights to all fibrosis assays and the targets discovered in the alliance. These novel targets were identified in various unique human primary cell assays mimicking fibrosis. Galapagos will have received a total of €16 million in upfront and milestone payments, including this latest payment.
Financial terms:
Latest news:
